Compare RAY & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAY | LEXX |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | Hong Kong | Canada |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 22.7M |
| IPO Year | 2024 | N/A |
| Metric | RAY | LEXX |
|---|---|---|
| Price | $1.61 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 63.2K | ★ 303.0K |
| Earning Date | 01-01-0001 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $10,120,519.00 | $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | $1.65 | ★ N/A |
| Revenue Growth | 17.57 | ★ 52.05 |
| 52 Week Low | $1.40 | $0.68 |
| 52 Week High | $58.88 | $2.43 |
| Indicator | RAY | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 32.14 |
| Support Level | $1.56 | $1.05 |
| Resistance Level | $1.68 | $1.44 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 28.21 | 3.47 |
Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Men's Care and Women's Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; neck care series; nail care series; tooling and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, handy fan and others. Raytech manufactures products under OEM and ODM.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.